1. PCRX's key patent was deemed invalid, threatening its main revenue source. 2. The stock fell over 47% after the unfavorable court ruling. 3. Shareholders can join a class action for potential recovery. 4. The lawsuit highlights increased risks of generic competitors. 5. The deadline for lead plaintiff registration is March 14, 2025.
The invalidation of PCRX's primary patent jeopardizes significant revenue and market position, similar to declines seen historically with patent disputes in biotech firms, such as the rapid decline of other firms post-patent invalidation.
The patent invalidation is critical for PCRX, impacting revenue and future competitive standing, making it highly relevant.
The long-term outlook is affected by potential future litigation and competition from generics, comparable to previous cases where market positions were permanently altered due to patent issues.
The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).
Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
August 2, 2023 to August 8, 2024
According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court "found that the company's U.S. Patent No. 11,033,495 (the '495 patent) is not valid," and, thus, eVenus is not infringing on anything. Pacira's '495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the '495 patent calls into question the validity of the Company's other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward. Following this news, Pacira's common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira's stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day.
March 14, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=132953&from=4
Once you register as a shareholder who purchased shares of PCRX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 14, 2025. There is no cost or obligation to you to participate in this case.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
The Gross Law Firm